Drug Target Review2026-07-14T09:00:00
Scientists at VCU Massey Comprehensive Cancer Center have developed an autophagy-targeting chimera that redirects cancer cells’ own recycling machinery to degrade the survival protein MCL1, offering a potential new strategy to overcome treatment resistance in multiple myeloma.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-18T11:12:00Z
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, Drug Target Review
2026-11-17T09:31:00Z
2026-08-24T08:43:00
Author Dr Dana Watt
2024-02-08T11:07:39
Sponsored by Samplix ApS
2025-08-05T13:42:00
Sponsored by ICON plc., Drug Target Review
2023-03-28T11:38:32
Sponsored by Bio-Techne
2026-10-30T07:00:00
Contributor Dr Shi-qi An, Drug Target Review
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
Site powered by Webvision Cloud